PTPN22 and myasthenia gravis: Because the PTPN22 R620W polymorphism demonstrates a wide variation among different populations, with the highest polymorphic allele presence being in Scandinavia (15%) yet absent in Asian and African populations [15], [27], this polymorphism is being investigated in this study as a susceptibility marker in MG patients and within heterogeneous disease subgroups from Turkey.